Literature DB >> 2904120

Antiparkinsonian activity of a single oral dose of PHNO.

F Grandas1, N Quinn, P Critchley, A Rohan, C D Marsden, S M Stahl.   

Abstract

PHNO, a new D-2 agonist, was investigated in five patients with Parkinson's disease. In an acute, open, oral, dose-ranging study comparing benefit from single doses, 4 mg of PHNO was found to be equivalent to one tablet of Sinemet 25/250 mg. Adverse reactions were those anticipated for a dopaminomimetic agent. Because of its novel structure and apparent transcutaneous penetration, further studies on PHNO are desirable.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2904120     DOI： 10.1002/mds.870020106

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  4 in total

1.  Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  C E Clarke; S Boyce; M A Sambrook; S M Stahl; A R Crossman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

2.  The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.

Authors:  W J Weiner; S A Factor; J R Sanchez-Ramos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

3.  Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease.

Authors:  S P Close; P J Elliott; A G Hayes; A S Marriott
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.

Authors:  R J Coleman; N P Quinn; M Traub; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.